TY - JOUR T1 - Predicting COVID-19 malignant progression with AI techniques JF - medRxiv DO - 10.1101/2020.03.20.20037325 SP - 2020.03.20.20037325 AU - Xiang Bai AU - Cong Fang AU - Yu Zhou AU - Song Bai AU - Zaiyi Liu AU - Qianlan Chen AU - Yongchao Xu AU - Tian Xia AU - Shi Gong AU - Xudong Xie AU - Dejia Song AU - Ronghui Du AU - Chunhua Zhou AU - Chengyang Chen AU - Dianer Nie AU - Dandan Tu AU - Changzheng Zhang AU - Xiaowu Liu AU - Lixin Qin AU - Weiwei Chen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/27/2020.03.20.20037325.abstract N2 - Background and purpose The worldwide pandemic of coronavirus disease 2019 (COVID-19) greatly challenges public medical systems. With limited medical resources, the treatment priority is determined by the severity of patients. However, many mild outpatients quickly deteriorate into severe/critical stage. It is crucial to early identify them and give timely treatment for optimizing treatment strategy and reducing mortality. This study aims to establish an AI model to predict mild patients with potential malignant progression.Methods A total of 133 consecutively mild COVID-19 patients at admission who was hospitalized in Wuhan Pulmonary Hospital from January 3 to February 13, 2020, were selected in this retrospective IRB-approved study. All mild patients were categorized into groups with or without malignant progression. The clinical and laboratory data at admission, the first CT, and the follow-up CT at the severe/critical stage of the two groups were compared. Both multivariate logistic regression and deep learning-based methods were used to build the prediction models, with their area under ROC curves (AUC) compared.Results Multivariate logistic regression depicted 6 risk factors for malignant progression: age >55years (OR 5.334, 95%CI 1.8-15.803), comorbid with hypertension (OR 5.093, 95%CI 1.236-20.986), a decrease of albumin (OR 4.01, 95%CI 1.216-13.223), a decrease of lymphocyte (OR 3.459, 95%CI 1.067-11.209), the progressive consolidation from CT1 to CTsevere (OR 1.235, 95%CI 1.018-1.498), and elevated HCRP (OR 1.015, 95%CI 1.002-1.029); and one protective factor: the presence of fibrosis at CT1 (OR 0.656, 95%CI 0.473-0.91). By combining the clinical data and the temporal information of the CT data, our deep learning-based models achieved the best AUC of 0.954, which outperformed logistic regression (AUC: 0.893),Conclusions Our deep learning-based methods can identify the mild patients who are easy to deteriorate into severe/critical cases efficiently and accurately, which undoubtedly helps to optimize the treatment strategy, reduce mortality, and relieve the medical pressure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Key R&D Program of China (No. 2018YFB1004600), HUST COVID-19 Rapid Response Call (No. 2020kfyXGYJ093, No. 2020kfyXGYJ094), National Key R&D Program of China (No. 2017YFC1309100), National Science Fund for Distinguished Young Scholars (No. 81925023), National Natural Science Foundation of China (No. 61703049, No. 81771912, No. 81401390).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe corresponding author had full access to all data and the final responsibility to submit for publication. ER -